Emergence of ST654 Pseudomonas aeruginosa co-harbouring blaNDM-1 and blaGES-5 in novel class I integron In1884 from Bulgaria
Multidrug-resistant (MDR) Pseudomonas aeruginosa is a common cause of hospital-acquired infections. Carbapenem resistance, in particular, represents a substantial problem in terms of treatment of infections due to this pathogen and leads to increased mortality, longer duration of hospital stay and increased healthcare costs [1]. The class B New Delhi metallo-β-lactamase 1 (NDM-1) carbapenemase has spread to and has been described in many bacterial species, including P. aeruginosa [2] Another carbapenemhydrolysing enzyme, the Guiana extended-spectrum β-lactamase-5 (GES-5), initially found in Escherichia coli in Greece and belonging to class A β-lactamase family, has also been detected in P. aeruginosa in Brazil, China, Spain and South Africa
Download publication
Related media library items
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
Background There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive R...
International and regional spread ofcarbapenem-resistant Klebsiella pneumoniae in Europe
Abstract Carbapenem-resistant Klebsiella pneumoniae (CRKP) are of particular concern due to the spread of antibiotic resistance genes associated with ...
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Data support that antibiotic aztreonam -avibactam (ATM-AVI) is effective and well- tolerated in treating infections caused by Gram-negative bacteri...